High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity - Summary - MDSpire
From the Journals

High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity

A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel led to a 100% measurable residual disease (MRD)-negativity rate in patients with high-risk smoldering ...

Share

The CAR-PRISM trial demonstrated that a single infusion of ciltacabtagene autoleucel, a CAR T-cell therapy, achieved a remarkable 100% measurable residual disease (MRD) negativity rate in high-risk smoldering multiple myeloma (SMM) patients. With high-risk SMM being a precursor to active multiple myeloma, this therapy represents a groundbreaking approach to intercept the disease early. Conducted by Dr. Omar Nadeem and team at Dana-Farber Cancer Institute, the trial highlights potential long-term benefits and raises questions about a cure through early intervention.

Original Source(s)

High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity

  • by The ASCO Post Staff

  • April 21, 2026

Related Content

Lung Cancer’s Hidden Layers

Study shows that tumor complexity can limit biopsy-based diagnosis

  • April 22, 2026

  • 2 min
Roving Reporter Asks: What Was the Biggest Development in CGT of 2025?

IBTV speaks with industry leaders at the 2025 Meeting on the Mesa to uncover the year’s defining breakthroughs

  • April 22, 2026

  • 1 min
Baptist Health Heart & Vascular Care Expands Interventional Radiology Program with Nine Physicians

 Baptist Health Heart & Vascular Care announces the addition of nine highly skilled interventional radiology physicians to Baptist Health Miami Cardiac & Vascular Institute, part of Baptist Health Heart & Vascular Care, further strengthening its commitment to advanced, minimally invasive care.

  • by

  • April 21, 2026

  • 3 min